Transplantation for Patients With Chronic Lymphocytic Leukemia

This study is ongoing, but not recruiting participants.

Sponsored by:	Stanford University
Information provided by:	Stanford University
ClinicalTrials.gov Identifier:	NCT00186303

Purpose

To evaluate the role of high dose therapy and autologous or allogeneic hematopoietic cell transplantation for the treatment of chronic lymphocytic leukemia.

Condition	Intervention
Leukemia, Lymphocytic, Chronic	Procedure: high dose chemotherapy then autologous hematopoietic cell transplant Procedure: ablative allogeneic hematopoietic cell transplant

MedlinePlus related topics: Leukemia, Adult Acute Leukemia, Adult Chronic

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study
Official Title:	Autologous and Allogeneic Peripheral Blood Progenitor (PBPC) Transplantation for Patients With Chronic Lymphocytic Leukemia

Further study details as provided by Stanford University:

Primary Outcome Measures:

Efficacy

Secondary Outcome Measures:

Feasibility
Toxicity
PCR for minimal residual disease

Estimated Enrollment:	28
Study Start Date:	November 1996

Detailed Description:

To determine effectiveness of allogeneic transplantation in eradicating chronic lymphocytic leukemia.

Eligibility

Ages Eligible for Study:	18 Years to 60 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:- adequate organ function

normal bone marrow cytogenetics
 Exclusion Criteria:- active CNS disease
For autologous patients more than 30% bone marrow involvement

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00186303

Locations

United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305

Sponsors and Collaborators

Stanford University

Investigators

Principal Investigator:

Robert S Negrin

Stanford University

More Information

Study ID Numbers:	BMT88, 77066, BMT88, NCT00186303
Study First Received:	September 13, 2005
Last Updated:	October 23, 2008
ClinicalTrials.gov Identifier:	NCT00186303
Health Authority:	United States: Institutional Review Board

Study placed in the following topic categories:

Chronic lymphocytic leukemia
Lymphatic Diseases
Leukemia
Leukemia, Lymphoid
Immunoproliferative Disorders

Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, B-cell, chronic
Lymphoproliferative Disorders
Leukemia, B-Cell

Additional relevant MeSH terms:

Neoplasms
Neoplasms by Histologic Type
Immune System Diseases

ClinicalTrials.gov processed this record on January 15, 2009